In addition to these data, complete results from the primary analysis of the phase 1 pharmacokinetics low-dose initiation (PK-LDI) study evaluating lower starting doses of MariTide were presented as part of an expert-led symposium at the 85th American Diabetes Association (ADA) Scientific Sessions and simultaneously published in The New England Journal of Medicine . Pfizer Inc
Do Ro and Brello offer genetic testing for GLP-1 response
Clinical manifestationsSymptoms and signs There are no specific symptoms or signs of MC: the symptoms are usually those derived from constipation
A total of three studies (923 high CVD risk) were pooled together
Conclusiones Los medicamentos basados en GLP-1 han transformado el manejo de la diabetes tipo 2 y la obesidad, ofreciendo beneficios significativos en el control glucmico, la prdida de peso y la reduccin de eventos cardiovasculares adversos
[1] [2] Para el control de peso (Zepbound), est indicada en adultos con un ndice de masa corporal (IMC) 30 kg/m, o 27 kg/m en presencia de al menos una comorbilidad relacionada con el peso